Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1380)	5/20/1998 3:35:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 2173

To All; Couple of points. The increase of insulin usage by the placebo group over time does not seem so certain to me. Why should they increase if they are stable. The trial should have been performed on stable(in their insulin usage) patients (say, over the previous 6 months). Even so, their will be variation in the usage in the use of insulin over time; such variation could probably have be statistically controlled by a proper statistical analysis, at least partially. I agree that possible tolerance to pramlintide could not be expected to occurr by the same mechanism that cancer cells develop tolerance to MOABs and other anti-cancer drugs. The mechanism in cancer cells is probably achieved by a Darwinian type of survival, selection, and growth of cells which are, by chance variation, tolerant (ie have some type of mechanism to eliminate) the MOAB or whatever type of cancer killing drug. Having said that, the physiology of the body is naturally oriented to maintain homeostasis, so there are a lot of mechanisms that the body uses to achieve this. I wouldn't totally eliminate the possibility of pramlintide tolerance buildup by some other mechanism. David